drugset
drugset / Trial / NCT07473973

ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

NCT07473973 ↗

Phase 3 Recruiting 12 enrolled Inozyme Pharma BioMarin Pharmaceutical · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.

Timeline

Start
2025-03-26
Primary completion
2028-09-11
Completion
2028-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject INZ-701 Protein / enzyme biologic — Subcutaneous

Indications

arterial calcification, generalized, of infancy, 1 autosomal recessive hypophosphatemic rickets